Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Sankyo Announces Details Of Its Ranbaxy Acquisition

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Daiichi Sankyo Aug. 11 announced details of its tender offer for Ranbaxy Laboratories, effective Aug. 16 through Sept. 4
Advertisement

Related Content

As Ranbaxy’s Regulatory Woes Persist, Imitrex Exclusivity Threatened
As Ranbaxy’s Regulatory Woes Persist, Imitrex Exclusivity Threatened
Daiichi Sankyo’s Deal With Ranbaxy Hits A Snag
Daiichi Sankyo’s Deal With Ranbaxy Hits A Snag
Ranbaxy CEO Malvinder Singh On U.S. FDA’s Investigation And The Daiichi Sankyo Deal: An Interview With PharmAsia News
Ranbaxy Denies Fraudulent Conduct Alleged By U.S. FDA As Rumors Swirl About Daiichi Deal
Japan’s Daiichi Sankyo In “Transformational” Deal to Buy Majority Stake In India’s Ranbaxy Labs
Japan’s Daiichi Sankyo In “Transformational” Deal to Buy Majority Stake In India’s Ranbaxy Labs
Daiichi Nets Novel HER-3 Antibody With U3 Acquisition
Advertisement
UsernamePublicRestriction

Register

SC069240

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel